Story thread · 2 reports / 2 sources
Elevar wins first FDA approval with second-line drug for bile duct cancer
endpts.com · 7h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
The FDA approved Elevar Therapeutics’ Lyrfigtu as a second-line treatment option for certain patients with bile duct cancer, which is diagnosed in about 8,000 Americans each year. Wednesday's green light for Lyrfigtu was based on ...
The coverage
- FDA Approves New Option for Previously Treated Bile Duct Cancer
medpagetoday.com · 4h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.